| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 175.86% | Wells Fargo | $4 → $2 | Maintains | Equal-Weight |
| 10/12/2023 | 2658.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 10/05/2023 | — | JonesTrading | Downgrades | Buy → Hold | |
| 09/25/2023 | 2658.62% | HC Wainwright & Co. | $18 → $20 | Maintains | Buy |
| 08/11/2023 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 08/11/2023 | 2382.76% | HC Wainwright & Co. | $19 → $18 | Maintains | Buy |
| 05/12/2023 | 2520.69% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/12/2023 | 1693.1% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 03/16/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/16/2023 | 2796.55% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 01/03/2023 | 1831.03% | Wells Fargo | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 2796.55% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 06/28/2022 | 2244.83% | Wells Fargo | $13 → $17 | Maintains | Overweight |
| 05/13/2022 | 1693.1% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 05/04/2022 | 1831.03% | Wells Fargo | $19 → $14 | Maintains | Overweight |
| 03/18/2022 | 2934.48% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 12/08/2021 | 2520.69% | Wells Fargo | → $19 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 2658.62% | HC Wainwright & Co. | $12 → $20 | Maintains | Buy |
| 07/20/2021 | 1831.03% | JonesTrading | → $14 | Initiates Coverage On | → Buy |
| 06/04/2020 | 1555.17% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 05/05/2020 | 1141.38% | HC Wainwright & Co. | $15 → $9 | Reiterates | → Buy |
| 03/13/2020 | 2382.76% | Wells Fargo | $30 → $18 | Maintains | Overweight |
| 07/29/2019 | 1968.97% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
What is the target price for Kezar Life Sciences (KZR)?
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by Wells Fargo on November 14, 2023. The analyst firm set a price target for $2.00 expecting KZR to rise to within 12 months (a possible 175.86% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by Wells Fargo, and Kezar Life Sciences maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a maintained with a price target of $4.00 to $2.00. The current price Kezar Life Sciences (KZR) is trading at is $0.73, which is out of the analyst's predicted range.